That's absolutely true. But I think there is another angle:
By broadcasting this highly negative appraisal, I think it's pretty clear R&R has had a marked effect upon share price, and that is how they affect the pricing of any transaction--they've reduced the 'floor.' If I were a sociopath and working at a company like R&R, I'd be trying to line up a private equity firm that had say, $75 million to put in. Buy Cortex at .75 a share (and here the options melt away since they are underwater), call it approx. $40 million with fees. With $35 million in operating capital, they could execute RD trials, a Euro ADHD trial, whatever it would take to dress Cortex up for resale for, call it $150 million. Double their money (or better) in 12 months. One can play with these figures, but the principle remains the same. R&R could broker it and also own a piece of the action.
Not that this will happen, but I believe that R&R is looking for more than just sending a message.
Ombow: I wrote that list of potential topics as a broad and time-consuming menu of possibilities. I'm not going to be able to go through them here . I've been spending way too much time posting here and getting riled up in the process, so I plan to do considerably less of both.
NeuroInvestment